New drug trial offers hope for Tough-to-Treat skin cancer patients
Disease control
Recruiting now
This study is testing an experimental drug called PTX-100 for adults with cutaneous T-cell lymphoma that has returned or hasn't responded to at least two previous treatments. Participants receive PTX-100 through IV infusions in repeating cycles for up to 18 months. The main goal …
Phase: PHASE2 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC